Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity

PARP inhibitors (PARPi) are under clinical trial for combination cancer chemotherapy. In the presence of a PARPi, PARP-1 binds DNA strand breaks but cannot produce poly(ADP-ribose) polymers or undergo auto-poly(ADP-ribosyl)ation. DNA binding is persistent, hindering DNA repair. Methylated bases form...

Descripción completa

Detalles Bibliográficos
Autores principales: Horton, Julie K., Wilson, Samuel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786324/
https://www.ncbi.nlm.nih.gov/pubmed/24137565
http://dx.doi.org/10.3389/fonc.2013.00257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786324/
https://www.ncbi.nlm.nih.gov/pubmed/24137565
http://dx.doi.org/10.3389/fonc.2013.00257

Ejemplares similares